Abstract 315: Directly Targeting Myocardial Fibrosis with FT-011 Improves Cardiac Remodeling in Experimental Diabetic Cardiomyopathy
The pathological accumulation of extracellular matrix (fibrosis) is a key contributor to cardiac dysfunction in diabetes and represents a major potential therapeutic target. The aim of this study was to test the efficacy of a novel anti-fibrotic drug, FT-011 (Fibrotech Therapeutics Pty Ltd, Melbourne, Australia), in a rodent model of diabetic cardiomyopathy. Male homozygous Ren-2 rats were randomized to streptozotocin or vehicle (n=8 per group). Diabetic and non-diabetic rats were further randomized to receive FT-011 (200mg/kg/day) or vehicle for 6 weeks. Prior to tissue collection, animals underwent echocardiography and Millar cardiac catheterization. Total collagen deposition and cardiomyocyte hypertrophy were assessed by picrosirius red and H & E staining, respectively. At 6 weeks, diabetic ren-2 animals developed cardiac dysfunction associated with cardiac fibrosis. FT-011-treated diabetic ren-2 rats had significantly reduced cardiac interstitial fibrosis along with reduced volumes and inter-cardiac pressures (Table⇓).